Short Interest in TransMedics Group, Inc. (NASDAQ:TMDX) Decreases By 13.3%

TransMedics Group, Inc. (NASDAQ:TMDX) was the recipient of a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 9,330,000 shares, a decline of 13.3% from the February 13th total of 10,760,000 shares. Currently, 29.9% of the company’s shares are short sold. Based on an average trading volume of 1,880,000 shares, the days-to-cover ratio is presently 5.0 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Clear Creek Financial Management LLC bought a new position in TransMedics Group during the fourth quarter worth $352,000. Vaughan Nelson Investment Management L.P. boosted its stake in TransMedics Group by 9.9% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock worth $22,547,000 after acquiring an additional 32,605 shares in the last quarter. Baillie Gifford & Co. boosted its stake in TransMedics Group by 14.9% during the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock worth $16,824,000 after acquiring an additional 34,947 shares in the last quarter. State of Michigan Retirement System bought a new position in TransMedics Group during the fourth quarter worth $6,734,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in TransMedics Group by 2.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after acquiring an additional 6,634 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on TMDX shares. Oppenheimer reissued an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. Piper Sandler reduced their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Canaccord Genuity Group reissued a “buy” rating and set a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, Robert W. Baird reduced their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Trading Down 2.1 %

NASDAQ:TMDX opened at $68.84 on Friday. The firm’s fifty day moving average is $68.12 and its 200-day moving average is $91.74. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $177.37. The firm has a market cap of $2.32 billion, a P/E ratio of 73.23 and a beta of 2.12.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.